Company Overview of Oncimmune Holdings plc
Oncimmune Limited develops and commercializes products for the detection of cancerous. It develops autoantibody assay technologies that have the potential to early detection a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test that is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company is based in Nottingham, the United Kingdom.
Clinical Sciences Building
Nottingham City Hospital
Nottingham, NG5 1PB
44 1158 231 869
44 1158 231 958
Key Executives for Oncimmune Holdings plc
Oncimmune Holdings plc does not have any Key Executives recorded.
Oncimmune Holdings plc Key Developments
Similar Private Companies By Industry
|ADC Biotechnology Ltd||Europe|
|Advanced Gel Technology Limited||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact Oncimmune Holdings plc, please visit www.earlycdt-lung.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.